

# Simona Leoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1833218/publications.pdf>

Version: 2024-02-01

23  
papers

1,721  
citations

623188

14  
h-index

752256

20  
g-index

23  
all docs

23  
docs citations

23  
times ranked

2404  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. <i>Hepatology</i> , 2005, 42, 27-34.	3.6	410
2	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3361-3373.	1.4	375
3	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. <i>Journal of Hepatology</i> , 2018, 68, 485-492.	1.8	195
4	The Impact of Vascular and Nonvascular Findings on the Noninvasive Diagnosis of Small Hepatocellular Carcinoma Based on the EASL and AASLD Criteria. <i>American Journal of Gastroenterology</i> , 2010, 105, 599-609.	0.2	185
5	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. <i>Liver International</i> , 2013, 33, 771-779.	1.9	91
6	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5888.	1.8	74
7	Characterization of liver lesions by real-time contrast-enhanced ultrasonography. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 3-14.	0.8	68
8	The role of ultrasound elastographic techniques in chronic liver disease: Current status and future perspectives. <i>European Journal of Radiology</i> , 2014, 83, 450-455.	1.2	57
9	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , 2014, 46, 549-555.	0.4	57
10	A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. <i>Liver Transplantation</i> , 2007, 13, 857-866.	1.3	45
11	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. <i>Hepatology</i> , 2021, 74, 2058-2073.	3.6	45
12	Treatment of hepatocellular carcinoma in Child-Pugh B patients. <i>Digestive and Liver Disease</i> , 2013, 45, 852-858.	0.4	32
13	Treatment of Combined Hepatocellular and Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 794.	1.7	32
14	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014, 20, 7049.	1.4	22
15	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, 729-734.	0.4	12
16	Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2022, 14, 2493.	1.7	7
17	Contrast-enhanced ultrasound in liver cancer. <i>Hepatic Oncology</i> , 2015, 2, 51-62.	4.2	6
18	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). <i>Cancers</i> , 2022, 14, 336.	1.7	5

#	ARTICLE	IF	CITATIONS
19	Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs. Translational Cancer Research, 2019, 8, S223-S232.	0.4	2
20	SAT-484-CEUS pattern of hepatocellular carcinoma: Prognostic implication. Journal of Hepatology, 2019, 70, e846.	1.8	1
21	Assessment of long-term prognosis at detection of early hepatocellular carcinoma remains unsolved. Journal of Hepatology, 2014, 61, 1438.	1.8	0
22	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology, 2021, 16, 653-661.	1.7	0
23	Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.. Journal of Clinical Oncology, 2013, 31, e15149-e15149.	0.8	0